Plain-English translation of NCT05698459 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage clinical trial testing a new treatment called OH2, which is an oncolytic virus designed to attack cancer cells. The medication is injected directly into liver tumors through a thin catheter (a small tube inserted into an artery). Researchers are studying whether this treatment is safe, how well patients tolerate it, and how the body processes it.
Many patients with advanced liver cancer do not respond well to standard treatments like chemotherapy or radiation, or cannot receive them safely. This trial explores whether a new type of therapy—a virus that specifically targets and kills cancer cells—could offer hope to patients who have limited treatment options.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will receive injections of the experimental medication directly into your liver tumor through a catheter procedure. The treatment is given once every 3 weeks. Researchers will monitor you closely with blood tests and imaging to evaluate your safety, how your body responds to the medication, and whether the tumor shrinks. The trial is small (enrolling about 12 patients total) and is focused on finding the safest and most effective dose.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Binhui Biopharmaceutical Co., Ltd.
Enrollment target
~12 participants
Started
May 2023
Primary completion
August 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in December 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
chuansheng zheng, MD
Binhui Biopharmaceutical Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.